啟愈生物將公布Q-1802臨床Ⅰ期數據
(醫藥健聞2022年12月21日訊)啟愈生物宣布,公司將在當地時間2023年1月19-21日于舊金山會場及線上舉行的美國臨床腫瘤學會胃腸道腫瘤研討會(ASCO Gastrointestinal Cancers Symposium)上展示其Q-1802項目的臨床Ⅰ期數據。該研究結果摘要將刊登于ASCO GI年會摘要匯集(#382),摘要概覽如下:
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs in patients with relapsed or refractory solid tumors
Authors: Yakun Wang1, Jifang Gong1, Yuping Sun2, Jian Zhang3, Yanqiao Zhang4 ,Shuqin ni2, Jie Hou5, Xiaohua Chen5, Yusheng Wang6, Qin Yu7, Xiangdong Qu8, Yejie Du8, Li Wei8, Tao Yu8, Lin Shen1
- Q-1802 is a humanized bispecific antibody
- targets both the tumor -specific antigen CLDN18.2 and the immune checkpoint PD-L1
- Q-1802 has excellent? safety, tolerability
- Q-1802 has excellent anti-tumor activity in CLDN18.2 positive GI patients
本文系作者個人觀點,轉載請注明出處!
賞
支付寶掃碼打賞
微信打賞